Abstract
An increasing number of newer targeted oncologic therapies approved for clinical use can cause drug-related pneumonitis. Drug-related pneumonitis can be difficult to diagnose and requires a high index of suspicion. This review serves as an update to a prior review in this journal about pneumonitis with precision oncology therapies. In this review, we focus on the incidence, timing of onset, and imaging patterns of pneumonitis associated with a number of newly approved precision oncologic agents, with a particular focus on new antibody-drug conjugate therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 272-282 |
| Number of pages | 11 |
| Journal | Journal of Immunotherapy and Precision Oncology |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 2024 |
Keywords
- antibody-drug conjugate
- pneumonitis
- precision oncology
- pulmonary adverse event
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS